Invited Speakers

  • Kitchener

    Prof Henry Kitchener

    Read biography

    close x
    Kitchener

    Prof Henry Kitchener

    Henry Kitchener is a Professor of Gynaecological Oncology at the University of Manchester and Honorary Consultant at St Mary’s Hospital and has been in this post since 1996.  The principal area of interest of his group is in clinical trials and all aspects of cervical neoplasia.  He is a Fellow of the Academy of Medical Sciences and is the Chair of the Department of Health Advisory Committee on Cervical Screening, the Chair of the Cancer Trials Awards & Advisory Committee (CTAAC), a member of the CRUK Science Committee and a Trustee of the British Society of Colposcopy and Cervical Screening.  He has previously Chaired the Gynecologic Cancer InterGroup (GCIG), the NCRI Gynaecological Clinical Studies Group, and the RCOG Academic Committee.

  • Professor Walter Prendiville

    Read biography

    close x

    Professor Walter Prendiville

    President Elect, Irish Society for Colposcopy and Cervical Pathology

    MAO FRCOG RCSI
    Co-Chairman Associate Professor and Consultant in Obstetrics & Gynaecology
    Coombe Women’s Hospital, Dublin, Republic of Ireland

  • Dr Eduardo Franco

    Read biography

    close x

    Dr Eduardo Franco

    Dr. Franco is James McGill Professor and Chair, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. Since 1985 his research has focused on the epidemiology and prevention of cancers of the uterine cervix and anogenital tract, upper aero-digestive tract, prostate, and childhood cancers. He published more than 380 articles, 55 chapters, and two books on the above topics. He is the Editor-in-Chief of Preventive Medicine and has served in the editorial boards of American Journal of Epidemiology, Cancer Detection and Prevention, Cancer Epidemiology, Biomarkers & Prevention, eLife, Epidemiology, International Journal of Cancer, Medical and Pediatric Oncology, and PLoS-Medicine. His distinctions include: Fellow of the Canadian Academy of Health Sciences (2012), Fellow of the Royal Society of Canada (2011), Lifetime Achievement Award, American Society for Colposcopy and Cervical Pathology (2010), Women in Government’s Leadership Award (2008), Canadian Cancer Society’s Warwick Prize (2004), Medical Research Council’s Distinguished Scientist Award (2000), and Educational Excellence at McGill (2000).

  • Dr. F. Xavier Bosch

    Read biography

    close x

    Dr. F. Xavier Bosch

    Dr. F. Xavier Bosch conducts epidemiological research focusing on cancers linked to infectious agents. His main research studies focus on cancer of the liver, the cervix, the skin, vagina, anus, penis and cancers of the head and neck. He has also conducted studies on diet and colorectal cancer and headed a program of implementation and methodological research in cancer registration.
    Dr. Bosch’s research projects on viruses and cancer have been instrumental in demonstrating the causal role of Human Papilloma Virus (HPV) in cervical cancer and played a catalytic role for the initiation of the first vaccine trials and for the evaluation of HPV tests as screening tools. Dr. F. Xavier Bosch was an early introducer of the now called molecular epidemiology, by designing studies that integrate novel biological assays at DNA level to assess exposure to viral carcinogens. Relevant epidemiological field studies have been carried out in over 35 countries around the world, particularly in Latin America, Africa and Asia. The final and more practical goal of his research has extended into the application of the aetiological knowledge to the prevention of cancer.

  • Professor Lynette Denny

    Read biography

    close x

    Professor Lynette Denny

    Professor Lynette Denny is a gynaecological oncologist by training and practice both general gynaecology and obstetrics. Since 1995 she have been collaborating with colleagues at investigating alternative strategies for the prevention of cervical cancer in low resource settings. They have to date performed 4 large clinical trials, the last being a randomised clinical trial that has had a significant impact on research and practice in many countries in Africa, Latin America and performed almost all coloposcopy and trained numerous doctors and nurses in the performance of this procedure. Professor Denny began a trial 8 years ago of following HIV positive women in an attempt to develop evidence based strategies for preventing cervical cancer in this vulnerable group and is very involved with the public sector of health in South Africa and is currently writing the policy for the Prevention of Cervical Cancer in at the invitation of the National Department of Health. She has been involved in drafting legal and health regulations for the management of sexual violence, termination of pregnancy and management of HIV infected mothers with the main focus of  research being cervical cancer prevention.

  • Professor Ian Frazer

    Read biography

    close x

    Professor Ian Frazer

    Professor Ian Frazer was trained as a renal physician and clinical immunologist in Edinburgh Scotland. In 1991, along with Chinese colleague, Dr Jian Zhou, he developed the virus-like particle technology which has become the basis of vaccines to prevent cervical cancer. Dr Frazer has recently been appointed as CEO and Director of Research of the newly created Translational Research Institute in Brisbane, Australia. He pursues research on skin cancer and on immunotherapy for cancer.

  • Dr Olaf Reich

    Read biography

    close x

    Dr Olaf Reich

    Dr. Olaf Reich is Professor of Gynecology at the Medical University of Graz and President of Austrian Society for Colposcopy. He was born in Leipzig, Germany, where he studied medicine and received a doctoral degree in 1985 from the University of Leipzig. He trained and became board certified in Pathology and Cytology at the University of Dresden. In 1994 he moved to the University of Graz were he trained in Obstetrics and Gynecology. He received a “Habilitation” in Gynecology in 2001 and Pathology in 2004. Dr. Olaf Reich has published in numerous peer-reviewed scientific journals, is co-author of medical textbooks. He is one of the Austria’s leading experts on Uterine Cervical Diseases, Colposcopy, and Vulvar Diseases.

  • Professor Julietta Patnick CBE

    Read biography

    close x

    Professor Julietta Patnick CBE

    Director, NHS Cancer Screening Programmes
    Visiting Professor in Cancer Screening, University of Oxford

    Julietta Patnick is the Director of the NHS Cancer Screening Programmes, which is now operated by Public Health England. She is responsible for overseeing the NHS Breast, Cervical and Bowel Cancer Screening Programmes and the Prostate Cancer Risk Management Programme.
    Professor Patnick first joined the NHS in 1979 and became involved in screening with the establishment of the breast screening programme in 1987. In 1990 Julietta Patnick was appointed National Coordinator of the NHS Breast Screening Programme and then in 1994 and subsequently, the role of National Coordinator of the NHS Cervical Screening Programme.  She later took responsibility for implementing the additional programmes in cancer screening and is now the Director of Cancer Screening for England.
    Julietta Patnick graduated in Ancient History and Classical Civilisation from SheffieldUniversity. She is a Fellow of the Faculty of Public Health.

  • Professor Jack Cuzick

    Read biography

    close x

    Professor Jack Cuzick

    Jack Cuzick is a director of Wolfson Institute of Preventive Medicine in London. He is also head of Centre for Cancer Prevention and John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York.
    His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role and also has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is also involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer. He is the statistician for several major breast cancer trials and maintains an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.
    He is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the the AACR Cancer Prevention Prize in 2012. He is the author of more than 480 peer-reviewed papers and has published in all the major medical journals.

  • Dr John Doorbar

    Read biography

    close x

    Dr John Doorbar

    PhD
    Group Leader, Division of Virology
    National Institute of Medical Research, London, UK

  • Dr Marc Arbyn

    Read biography

    close x

    Dr Marc Arbyn

    Scientific Institute of Public Health, Brussels, Belgium

    Marc Arbyn obtained his MD diploma in 1984 at the University of Ghent (Belgium); he obtained diplomas of Dr in tropical medicine and a MSc degree in tropical epidemiology at the Institute of Tropical Medicine in Antwerp.  After a career of 10 years in Africa with Médecins Sans Frontières, he got involved in cancer research in Europe.  Marc Arbyn coordinated the evaluation of new screening methods in the framework of the European Network of Cervical Cancer Screening and is editor- of the 2nd edition of European Guidelines for Cervical Cancer Screening (2008). One of his main activities deals with systematic reviews, Cochrane reviews and meta-analyses regarding cervical cancer screening, diagnosis and treatment of screen detected cervical cancer precursors and HPV vaccination.  Another point of his interests consists in trend and spatial analysis of cancer incidence and mortality. Since 2007, M. Arbyn is steering group member or coordinator of several international networks involved in biobank-based cancer research that addresses etiological questions and possible application of biomarkers in screening, diagnosis and prognosis prediction. Over the last two years, MA was author of 47 papers, published in peer-reviewed journals (see list below) and a dozen of book chapters.

  • Professor Silvio Tatti

    Read biography

    close x

    Professor Silvio Tatti

    Presidente de la Federación Internacional de Colposcopia: IFCPC
    Chairman Advisory Group Cervical Cancer Initiative. UICC Unión Internacional contra el Cáncer

    Buenos Aires, Argentina

  • profile_image_Cruickshank_Margaret

    Dr Margaret E Cruickshank

    Read biography

    close x
    profile_image_Cruickshank_Margaret

    Dr Margaret E Cruickshank

    President, British Society of Colposcopy and Cervical Pathology
    MB ChB MD FRCOG
    Division of Medical and Dental Education
    University of Aberdeen

    I am a Senior Clinical Lecturer/Honorary Consultant Gynaecologist at the University of Aberdeen with a special interest in colposcopy and vulva disorders.  I am currently President of the British Society for Colposcopy and Cervical Pathology. The focus of my research relates to HPV and investigating the impact of HPV immunisation on cervical screening and colposcopy performance.